Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both genders~* Age ≥ 18 years old~* Give written informed consent to participate in the study after having been informed of the study design, objectives and possible derived risks~* Common mild to moderate dry eye symptoms. Persistent daily symptoms for more than three months:~* OSDI scale: 13-30~* VAS scale: 2-7~* Ocular tests in both eyes:~* Corneal staining with fluorescein. Oxford scale \> 0~* Tear Breakup Time Test: (BUT) \< 10 seconds~* Schirmer test with anaesthesia \< 10 mm/5min~Exclusion Criteria:~* Pregnant or breastfeeding females or those with a positive pregnancy test.~* Females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the whole study.~* Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplasic, hepatopathy, gastrointestinal distress, hypertension, or infectious acute processes.~* Past history of a chronic o recurring condition that could interfere with study according to the investigator's judgement.~* Concomitant use of other drugs with analgesic activity by any route of administration at the enrolment period.~* Changes in any ocular and/or systemic concomitant medication one month prior to the study commencement and during the study development.~* Changes on the preestablished artificial tears dosage 15 days prior to the study commencement and during the study development.~* Cyclosporine treatment initiation or changes in cyclosporine dosage or dosing regimen during the 6 months prior to enrolment.~* Previous history of drug hypersensitivity.~* Use of contact lenses~* Case history of drug or alcohol abuse or dependence.~* Relevant abnormal laboratory results as judged by the investigator~* Previous refractive surgery~* Participation in a clinical trial within 2 months before the enrolment visit~* Relevant ocular pathology judged by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SYL1001 eye drops dose A (Type: EXPERIMENTAL): Ocular topical administration of SYL1001 eye drops dose A
- Placebo (Type: PLACEBO_COMPARATOR): Ocular topical administration of placebo eye drops

Based on this trial design, predict the completion outcome and termination type (if applicable).